We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA: One Patient’s Unique Experience Misleads on Efficacy in Novartis Aid
FDA: One Patient’s Unique Experience Misleads on Efficacy in Novartis Aid
October 3, 2012
Novartis’ use of case studies in cancer drug Gleevec’s advertising material is misleading because one patient’s experience does not count as substantial evidence, the FDA says.